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The Journal of Immunology
Human Invariant NKT Cell Subsets Differentially Promote
Differentiation, Antibody Production, and T Cell Stimulation
by B Cells In Vitro
Shijuan Grace Zeng,*,1 Yasmeen G. Ghnewa,* Vincent P. O’Reilly,* Victoria G. Lyons,*
Ann Atzberger,*,2 Andrew E. Hogan,† Mark A. Exley,‡ and Derek G. Doherty*
Invariant NK T (iNKT) cells can provide help for B cell activation and Ab production. Because B cells are also capable of cytokine
production, Ag presentation, and T cell activation, we hypothesized that iNKT cells will also influence these activities. Furthermore,
subsets of iNKT cells based on CD4 and CD8 expression that have distinct functional activities may differentially affect B cell
functions. We investigated the effects of coculturing expanded human CD4+, CD8a+, and CD42CD8a2 double-negative (DN)
iNKT cells with autologous peripheral B cells in vitro. All iNKT cell subsets induced IgM, IgA, and IgG release by B cells without
needing the iNKT cell agonist ligand a-galactosylceramide. Additionally, CD4+ iNKT cells induced expansions of cells with
phenotypes of regulatory B cells. When cocultured with a-galactosylceramide–pulsed B cells, CD4+ and DN iNKT cells secreted
Th1 and Th2 cytokines but at 10–1000-fold lower levels than when cultured with dendritic cells. CD4+ iNKT cells reciprocally
induced IL-4 and IL-10 production by B cells. DN iNKT cells expressed the cytotoxic degranulation marker CD107a upon
exposure to B cells. Remarkably, whereas iNKT cell subsets could induce CD40 and CD86 expression by B cells, iNKT cell–
matured B cells were unable to drive proliferation of autologous and alloreactive conventional T cells, as seen with B cells cultured
in the absence of iNKT cells. Therefore, human CD4+, CD8a+, and DN iNKT cells can differentially promote and regulate the
induction of Ab and T cell responses by B cells. The Journal of Immunology, 2013, 191: 1666–1676.
I
nitiation of T cell–dependent B cell responses involves en-
gagement of Ag by the BCR, resulting in Ag internalization,
processing, and cell-surface presentation on MHC molecules
(1–3). Upon recognition of cognate peptide–MHC class II com-
plexes, the T cell upregulates CD40L, which engages CD40 on the
B cell, inducing proliferation and differentiation. The T cell also
secretes cytokines that are required for Ig isotype switching.
Cognate T cell–B cell interactions can result either in extra-
follicular proliferation of B cells into short-lived plasmablasts that
do not undergo affinity maturation and mediate transient innate-
like responses (2) or germinal center proliferation of B cells,
which undergo somatic hypermutation and affinity maturation,
resulting in the generation of long-lived plasma cells or memory
B cells (3).
Invariant NKT (iNKT) cells can provide help for B cell matu-
ration and Ab production. iNKT cells are cytotoxic T cells that
express a TCR composed of an invariant a-chain (Va14Ja18 in
mice and Va24Ja18 in humans) that pairs with a limited number
of b-chains and recognizes glycolipid Ags presented by the MHC
class I–like molecule CD1d (4, 5). iNKT cells are thought to play
central roles in innate and adaptive immunity through their ability
to activate or induce differentiation of NK cells (6), dendritic cells
(DC) (4, 7, 8), and T cells (9) and to release multiple Th cell–
polarizing cytokines (10–13). iNKT cells can also regulate, en-
hance, and sustain humoral immune responses. In murine models,
CD1d and iNKT cells are required for the generation of protective
Ab responses against pathogens, including Plasmodium falcipa-
rum (14), Streptococcus pneumoniae (15), and Borrelia species
(16). CD1d and iNKT cells are also required for the production of
allergen-specific IgE in an experimental asthma mouse model
(17). The adjuvant effect of iNKT cells on humoral immune
responses is Ag specific. Coadministration of the iNKT cell ag-
onist ligand a-galactosylceramide (a-GC) with immunizing Ag to
mice results in enhanced production of Abs specific for the Ag
(18–20). This help provided by iNKT cells results in the induction
of long-lived Ab-secreting plasma cells, affinity maturation, and
the generation of memory B cells (20–22). iNKT cells can also
provide help for B cells specific for lipid-containing Ags inter-
nalized through the BCR (23, 24). Such B cell help results in the
formation of extrafollicular plasmablasts and germinal centers,
affinity maturation, and robust IgG Ab responses but not long-
lived memory cells (25).
Although iNKT cells express semi-invariant TCRs, they can be
divided into distinct populations based on CD4 and CD8 expres-
sion. Humans have varying ratios of CD4+CD82 (CD4+), CD42
*Department of Immunology, School of Medicine, Trinity College Dublin, Dublin 8,
Ireland; †Obesity Research Group, Education and Research Centre, St. Vincent’s Hos-
pital, Dublin 4, Ireland; and ‡Division of Gastroeneterology, Brigham and Women’s
Hospital, Harvard Medical School, Boston, MA 02215
1Current address: Institutional Review Board, National University of Singapore,
Singapore.
2Current address: Heidelberg Institute for Stem Cell Technology and Experimental
Medicine, Heidelberg, Germany.
Received for publication August 9, 2012. Accepted for publication June 8, 2013.
This work was supported by grants from the Irish Health Research Board (to S.G.Z.
and V.P.O.), Science Foundation Ireland (to A.E.H.), and the Irish Research Council
(to Y.G.G.), and by National Institutes of Health Grant CA143748 and CA170194 (to
M.A.E.).
Address correspondence and reprint requests to Dr. Derek G. Doherty, Department of
Immunology, School of Medicine, Institute of Molecular Medicine, St. James’s Hos-
pital, Trinity College Dublin, Dublin 8, Ireland. E-mail address: derek.doherty@tcd.
ie
Abbreviations used in this article: Breg, regulatory B cell; CBA, cytometric bead
array; DC, dendritic cell; DN, double-negative; a-GC, a-galactosylceramide; FMO,
fluorescence minus one (flow cytometry control); iDC, immature dendritic cell;
iNKT, invariant NKT; MFI, mean fluorescence intensity; MZB, marginal zone
B cell; PD-1, programmed cell death-1; PPD, purified protein derivative of tubercu-
lin; SEB, Staphylococcal enterotoxin B; TFH, follicular Th.
Copyright 2013 by TheAmericanAssociation of Immunologists, Inc. 0022-1767/13/$16.00
www.jimmunol.org/cgi/doi/10.4049/jimmunol.1202223
 at M
aynooth U
niversity (Natl Univ of Ireland) on February 11, 2020
http://w
w
w
.jimmunol.org/
D
ow
nloaded from
 
CD8a2b2 (double-negative [DN]), and CD42CD8a+b2 (CD8a+)
iNKT cells (11, 13, 26). CD4+ iNKT cells release the most Th2
cytokines, and CD8a+ and DN iNKT cells predominantly exhibit
Th1 phenotypes and cytotoxic activity (11, 13, 27). To date, two
studies (28, 29) have examined the relative contributions of human
iNKT cells subsets to B cell help and found that both CD4+ and
CD42 iNKT cells similarly induced B cell proliferation, but CD4+
iNKT cells induced higher levels of Ab production.
In addition to their roles in Ab production, B cells are potent
APCs that can prime CD4+ T cells without the participation of DC
or macrophages (30). Similar to DC, B cells can produce both
Th1- and Th2-type cytokines and can be polarized toward one or
the other subset subsequent to interaction with CD4+ Th1 or Th2
cells (31). The unique abilities of iNKT cells to selectively secrete
Th1, Th2, Th17, or regulatory T cell cytokines (10–13) and to
induce DC maturation (7, 8, 32) led us to hypothesize that
iNKT cells may exert stimulatory and/or regulatory control over
Ag presentation and T cell activation by B cells. In this study, we
have examined the outcomes of culturing human peripheral
B cells with expanded autologous iNKT cells or sorted CD4+,
CD8a+, and DN iNKT cell subsets in vitro in the absence or
presence of a-GC. We show that the iNKT cell subsets differen-
tially induce phenotypic differentiation, Ab secretion, and T cell
stimulation by B cells. We also show that CD4+ iNKT cells pro-
mote the development of cells with phenotypes of regulatory B
(Breg) cells and the production of IL-10 by some B cells. Thus,
CD4+, CD8a+, and DN iNKT cells can differentially promote
T cell or Ab responses via their interactions with B cells. This
observation has implications for iNKT cell–based therapies for
cancer and autoimmune disease, which may require the selective
targeting of functionally distinct subsets of iNKT cells.
Materials and Methods
Abs and flow cytometry
Fluorochrome-conjugated mAbs specific for human CD1d, CD3, CD4,
CD5, CD8a, CD19, CD20, CD22, CD24, CD27, CD38, CD40, CD58,
CD69, CD80, CD83, CD86, CD95, CD107a, HLA-DR, IFN-g, IL-4, IL-
10, IL-13, IL-21, the TCR Va24 and Vb11 chains, the CDR3 of the
iNKT cell TCR (6B11), CXCR5, programmed cell death-1 (PD-1), and
isotype control mAbs were purchased from Immunotools (Friesoythe,
Germany), eBioscience (Hatfield, U.K.), Bio Legend (San Diego, CA), and
BD Biosciences (Oxford, U.K.). A total of 105 cells were labeled with
mAbs and analyzed using a CyAN ADP flow cytometer (Beckman
Coulter, High Wycombe, U.K.). Data were analyzed with the Summit
v4.3 software (DakoCytomation) and FlowJo v7.6 (Tree Star). In cocul-
tures of expanded iNKT cells and B cells, iNKT cells were analyzed by
gating on the CD3+6B11+ lymphocytes and on their CD4+, CD8+, and
DN subsets. Follicular Th (TFH) cells were defined as CXCR5
+PD-1+ or
IL-21+. B cells were analyzed by gating on CD19+ lymphocytes, and B cell
subsetswere defined as naive (CD272IgD+), unswitchedmemory (CD27+IgD+),
switched memory (CD27+IgD2), CD272 memory (CD272IgD2) B cells,
and two putative Breg cell subsets (CD1dhiCD5+ and CD24hiCD38hi).
Single stained controls were used to set compensation parameters, and
fluorescence-minus-one (FMO) and isotype-matched Ab controls were
used to set analysis gates.
Isolation of human B cells
PBMC were isolated from blood samples obtained from healthy donors or
from buffy coat packs (kindly provided by the Irish Blood Transfusion
Service) by density gradient centrifugation over Lymphoprep (Nycomed
Pharma, Oslo, Norway). B cells were purified by magnetic bead sorting
using CD19 microbeads (Miltenyi Biotec, Bergisch Gladbach, Germany),
and purity of B cells was determined to be .99% by flow cytometric
analysis of CD20 expression. Enriched B cells were cryopreserved or
maintained in iNKT cell medium, which consisted of RPMI 1640 con-
taining 0.05 mM L-glutamine, 10% v/v HyClone FBS (Thermo-Scientific,
Logan, UT), 0.02 M HEPES buffer, 100 U/ml penicillin, 100 mg/ml
streptomycin, 2.5 mg/ml amphotericin B Fungizone, 13 MEM nones-
sential amino acids, and 0.05 mM 2-ME (Life Technologies BRL, Paisley,
U.K.).
Generation of monocyte-derived DC
Monocytes were enriched to .90% purity from PBMC by positive se-
lection using CD14 microbeads (Miltenyi Biotec). The monocytes were
allowed to differentiate into immature DC (iDC) by culturing them for
6 d in the presence of GM-CSF and IL-4 as described previously (32).
Flow cytometry was used to verify that differentiation into iDC had taken
place and cells expressed HLA-DR and CD11c but not CD14.
Generation of iNKT cell lines
iNKT cells were enriched from PBMC by staining with a PE-conjugated
anti-iNKT cell mAb (clone 6B11) followed by positive selection of the
PE-positive cells by magnetic bead separation (Miltenyi Biotec). In later
experiments, anti-iNKT cell microbeads were used. Enriched iNKT cells
were then purified to .99% purity by flow cytometric sorting of CD3+
Va24+Vb11+ cells using a MoFlo XDP Cell Sorter (Beckman Coulter).
Sorted iNKT cells were cultured in iNKT cell medium and expanded by
one of two methods described previously (13, 32). In the first method,
iNKT cells were subjected to a single stimulation with plate-bound anti-
CD3 (HIT3A) mAb (BD Biosciences) in the absence of irradiated feeder
cells and cultured in the presence of rIL-2. In the second method,
iNKT cells were stimulated with PHA in the presence of irradiated allo-
geneic PBMC and IL-2. Purity and phenotype of iNKT cell lines were
assessed by flow cytometry after staining the cells with mAbs specific for
CD3, 6B11, CD4, and CD8. Both methods resulted in 750–1000-fold
enrichment of iNKT cells and yielded cell lines of which .98% displayed
6B11+CD3+ phenotypes (Fig. 1A). iNKT cell lines were phenotyped for
expression of CD4 and CD8a (Fig. 1B) and means of 20 6 21, 68 6 26,
and 11 6 8% of 6B11+ cells were CD4+, DN and CD8a+, respectively
(Fig. 1C). Expanded iNKT cell lines were further sorted into CD4+, CD8+,
and DN cells by MoFlo (Beckman Coulter) cell sorting.
Coculture of B cells with iNKT cells
B cells were cocultured with iNKT or as controls non-iNKT cells (total
PBMC expanded with anti-CD3 mAb or PHA and IL-2 as done with
iNKT cells) for 3 or 10 d at 1:1 ratios in 96-well round-bottom plates
(Corning Life Sciences) at cell densities of 106 cells/ml. The following
stimulators or blockers were added: 100 ng/ml a-GC (Funakoshi, Tokyo,
Japan), 10 ng/ml PMA, and 1 mg/ml ionomycin (both from Sigma-Aldrich)
and 10 mg/ml each of anti-CD1d, anti-CD40, anti-CD154, anti–IL-4, and
anti–IL-13 mAb. Before adding to cultures, a-GC was subjected to heat-
ing, sonication, and vortexing as described previously (13). Supernatants
were harvested and frozen at 220˚C until they were analyzed for cytokine
FIGURE 1. Expansion of iNKT cell subsets. (A) Flow cytometric
analysis of CD3 and the Va24Ja18 TCR (6B11) expression by freshly
isolated PBMC and a 6-wk-old iNKT cell line. Plots are representative of
iNKT lines generated from 10 healthy donors. (B) Flow cytometric anal-
ysis of CD4 and CD8 expression by expanded iNKT cells after electron-
ically gating on CD3+6B11+ cells. (C) Mean proportions of CD4+, DN, and
CD8+ iNKT cell subsets found in seven iNKT cell lines.
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and Ig production. Cells were recovered for phenotypic analysis by flow
cytometry or for use as stimulators of T cells.
Analysis of cytokine and Ab secretion
Cytometric bead array (CBA) kits were used to quantify the levels of
cytokines and Igs in supernatants from the B–iNKT cell cocultures,
according to the manufacturer’s instructions (BD Biosciences). The
cytokines assayed for were IFN-g, IL-2, IL-4, IL-5, IL-6, IL-10, IL-12p70,
and IL-13. The Igs assayed for were IgA, IgM, total IgG, IgG1, IgG2, and
IgE. Flow cytometric data were generated using a CyAN ADP flow
cytometer (Beckman Coulter), and geometric means of the individual bead
populations were analyzed using Summit v4.3 software (DakoCytoma-
tion). GraphPad Prism v5.0 (GraphPad Software, La Jolla, CA) was used to
draw standard curves and obtain sample concentration values.
Analysis of intracellular cytokine production by iNKT cell and
B cell subsets
Total B cells were cocultured for 3 d in medium alone or with equal numbers
of sorted CD4+ iNKT cells in the absence or presence of a-GC as described
above. Monensin (0.05 mM; Sigma-Aldrich) was added for the last 4 h to
promote intracellular accumulation of cytokines. Cells were then washed
and stained for cell surface expression of 6B11, CD19, CD1d, CD5, CD24,
and CD38 and intracellular expression of IFN-g, IL-10, IL-4, and IL-21
using fluorochrome-conjugated mAb obtained from BD Biosciences or
eBioscience and analyzed by flow cytometry (13).
Cytotoxicity assays
Cytolytic degranulation by iNKT cells in response to B cells in the absence
and presence of a-GC was examined by analysis of cell-surface CD107a
expression. iNKT cells and B cells were cocultured for 4 h at 1:1 ratios in
the presence of anti-CD107a PE-Cy7 mAb. Monensin (2 mM) was added
after 1 h to prevent proteolysis of the mAb conjugate upon reinternaliza-
tion of CD107a. Frequencies of CD107a expression by iNKT subsets were
determined by flow cytometry after electronically gating on CD4+, DN,
and CD8a+ subsets.
Analysis of the capacity of B cells to drive T cell proliferation
B cells were cocultured with equal numbers of autologous iNKT cells at
densities of 106 cells of each type per milliliter in the presence or absence
of 100 ng/ml a-GC for 3 d. B cells and iNKT cells were also cultured
separately in medium alone as negative controls. The cocultured cells were
harvested, washed, and examined for expression of CD40, CD69, CD80,
CD83, CD86, and HLA-DR by flow cytometry or used as stimulators for
autologous or allogeneic conventional T cells that were enriched by
magnetic selection using CD3 microbeads (Miltenyi Biotec). The T cells
were labeled using the CellTrace Violet Cell Proliferation Kit following
the manufacturer’s instructions (Invitrogen, Paisley, U.K.) and cultured
with the B/iNKT cells at ratios of 3:1 with the following stimuli: medium
only (negative control), 10 mg/ml purified protein derivative of tuberculin
(PPD; Statens Serum Institut, Copenhagen, Denmark) (4), 1 mg/ml Staphy-
lococcal enterotoxin B (SEB; Sigma-Aldrich) (4), or 5 mg/ml PHA (Sigma-
Aldrich). Proliferation of the T cells was assayed by flow cytometric exami-
nation of dilution of the CellTrace dye after 6 d in culture. Acquired data were
analyzed using FlowJo v7.6 (Tree Star).
Statistical analyses
Statistical analysis was performed using GraphPad Prism v5.0 (GraphPad).
For comparison between two groups, the Mann–WhitneyU test was used to
compare unpaired data, and the Wilcoxon matched-pairs test was used to
compare paired data. For comparison among three or more groups, the
Kruskal–Wallis test was used to compare unpaired data, and the Fried-
man’s test was used to compare paired data. Dunn’s multiple comparison
tests were performed post hoc to compare individual groups within an
experiment. Two-way ANOVAwith post hoc Bonferroni’s test was used to
compare the effect of treatments.
Results
CD1d is uniformly expressed across all B cell subsets
PBMC from seven healthy donors were stained with mAbs specific
for CD19 and CD1d and CD5, CD22, CD38, or CD27, which detect
B-1, mature, plasma, and memory B cells, respectively (Fig. 2).
CD1d expression by each B cell subset was determined by com-
paring the intensity of staining with anti-CD1d mAb with that of
the corresponding FMO control, in which the anti-CD1d mAb was
omitted (Fig. 2A). Up to 30% of circulating B cells expressed
phenotypes associated with plasma cells, whereas 19–44% were
B-1 cells and 12–31% were memory cells (Fig. 2B). CD1d was
expressed at the cell surface of similar proportions (48–92%) of
each B cell subset. Memory B cells displayed the highest pro-
portion of CD1d expression (Fig. 2C), whereas the mean fluo-
rescence intensity (MFI) of CD1d expression was also highest
on this B cell subset. (Fig. 2D). One-way ANOVA showed no
significant difference between the mean proportions of or MFI of
CD1d expression on each B cell subset. Whereas CD1d expression
by B cells is reported to be downregulated by activation (33), we
found that coculturing with iNKT cells did not affect the level of
CD1d expression (Fig. 2E).
CD4+, DN, and CD8a+ iNKT cells can induce secretion of
IgG, IgA, and IgM, but not IgE, by B cells
iNKT cells can provide help to B cells for the production and
secretion of Abs in vivo (18–24). We investigated whether sorted
subsets of CD4+, DN, and CD8a+ iNKT cells differed in their
capacity to induce Ab production. Initially, B cells were cultured
with total iNKT cells or non-iNKT cells in the absence of added
Ag, and cell supernatants were removed after 3 d (data not shown)
or 10 d (Fig. 3A) and assayed for Ab production by multiplex
CBA analysis. Relative to B cells cultured alone, there was in-
creased production of IgA and IgM (p , 0.05) after 3 d of culture
with iNKT cells and of total IgG (p , 0.01), IgM, and IgA (p ,
0.05) after 10 d of B cell coculture with iNKT (Fig. 3A). In
contrast, non-iNKT cells did not induce the release of these Abs
by the same B cells. No IgE was detected in any of the stim-
ulations or cocultures (data not shown). When sorted subsets of
CD4+, DN, and CD8+ iNKT cells were cultured for 10 d with
B cells, all three subsets induced IgM, IgA, and IgG production
(Fig. 3B). Surprisingly, the addition of a-GC to the cocultures did
not result in enhanced Ab production. The activation of B cells in
the absence of a-GC may thus be due to the presence of a self-
glycolipid presented by CD1d on the B cell.
To investigate the requirements for cell–cell contact and for
CD1d and cytokines in iNKT cell–mediated B cell help for Ab
production, B cells were cultured alone or with equal numbers of
total iNKT cells for 10 d together or separated using transwell
plates and in the absence or presence of blocking Abs against
CD1d, IL-4, IL-13, CD40, or CD154. Supernatants from the
cocultures were removed and assayed for IgG, IgM, and IgA re-
lease. When B cells and iNKT cells were separated in transwell
plates or when blocking Abs against CD1d were added to the
iNKT–B cell cocultures, Ab secretion was inhibited (see Fig. 3C
for IgA). When anti–IL-4, anti–IL-13 (Fig. 3C), anti-CD40, or
anti-CD154 mAbs (Fig. 3D) were added to the cultures, there was
no inhibition of IgG, IgM, or IgA release, and the anti-CD40 mAb
may have a weak agonistic effect on B cell activation. Therefore,
all three subsets of human iNKT cells can provide B cell help for
Ab production by a mechanism that requires cell contact and
CD1d but not a-GC and does not appear to require CD40–CD154
interactions or Th2 cytokine secretion.
CD4+ iNKT cells induce the expansion of unswitched memory
and CD1dhiCD5+ B cells
Total B cells were cultured for 3 or 10 d in medium alone or with
equal numbers of expanded total, CD4+, CD8+, or DN iNKT cells
or non-iNKT cells (PBMC expanded by anti-CD3 mAb and IL-2).
Changes in the percentages of naive (CD272IgD+), unswitched
memory (CD27+IgD+), switched memory (CD27+IgD2), and
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CD272 memory (CD272IgD2) B cells and two putative Breg cell
subsets (CD1dhiCD5+ and CD24hiCD38hi) (34, 35) were analyzed
by flow cytometry. The expression of the TFH (CXCR5
+PD-1+)
phenotype (36, 37) by the iNKT cells was also examined. Total
and CD4+ iNKT cells, but not CD8+ nor DN iNKT cells, in the
presence of a-GC induced modest expansions of unswitched
memory B cells (28–46%) after 10 d with concomitant reductions
in naive B cells (35–22%) by a mechanism that required cell–cell
contact (data not shown). However, the numbers of switched and
CD272 memory B cells were unaffected. Sorted CD4+ iNKT cells
also induced significant expansions of CD1dhiCD5+ B cells (Fig.
4A, 4B). In contrast, CD8+ and DN iNKT cells induced upregu-
lation of CD5 but not CD1d on B cells. Induction of CD1dhiCD5+
B cells by CD4+ iNKT cells required cell–cell contact but not
prior activation of the iNKT cells with a-GC. CD4+ iNKT cells
in the presence of a-GC also induced a moderate expansion of
CD24hiCD38hi B cells (Fig. 4B). These results provide evidence
that resting CD4+ iNKT cells may induce the differentiation of
Breg cells in vitro.
Although iNKT cells provided B cell help for Ab secretion
(Fig. 3), ,2% of CD4+, CD8a+, or DN expressed the CXCR5+
PD-1+ phenotype found on TFH cells and murine iNKT cells
(36, 37). The presence of B cells or a-GC did not significantly
alter the frequencies of iNKT cells that express TFH phenotypes
(Fig. 4C).
B cells present a-GC to CD4+ and DN iNKT cells resulting in
the release of low levels of IFN-g, TNF-a, IL-4, IL-5, IL-10,
and IL-13
The ability of B cells to present a-GC to iNKT cells resulting in
cytokine release was investigated by coculturing B cells alone or
with autologous sorted CD4+, DN, or CD8+ iNKT cells in the
absence or presence of a-GC. Cell supernatants were removed
after 3 d and assayed for cytokine levels by multiplex CBA
FIGURE 2. CD1d is uniformly expressed across all human B cell subsets. (A) Representative flow cytometry dot plot showing the identification of B cell
subsets and the gating strategy for measuring CD1d expression by B cell subsets (top panel). The bottom left panel shows the FMO control lacking the anti-
CD1d mAb, whereas the bottom right panel shows CD1d expression. (B) Proportions of B cell subsets in peripheral blood of seven donors. (C) Proportions
of B cell subsets that express cell-surface CD1d. Horizontal lines represent means from seven donors. (D) Average (6 SEM) MFI of CD1d expression by B
cell subsets. One-way ANOVA showed that there were no significant differences in CD1d expression between the subsets. (E) Average (6 SEM) MFI of
CD1d expression by total B cells cultured for 3 d in the absence and presence of iNKT cells and a-GC.
FIGURE 3. CD4+, CD8+, and DN iNKT cells induce secretion of IgG, IgA, and IgM, but not IgE, by B cells. (A) Levels of IgM, IgG, and IgA in
supernatants from 10-d cultures of B cells, iNKT cells, and cocultures of B cells with iNKT cells or non-iNKT cells (PBMC expanded by anti-CD3 mAb
and IL-2 stimulation). IgE was also assayed for and not detected in any cultures. Bars represent means 6 SEM from three independent experiments. (B)
Levels of IgM, IgG, and IgA released by B cells cultured for 10 d in medium alone or with CD4+, CD8+, or DN iNKT cells, in the absence or presence of
100 ng/ml a-GC. Results are means 6 SEM from seven experiments. (C and D) Levels of IgA in supernatants of B cells cultured for 10 d in medium alone
or with iNKT cells in the absence or presence of blocking mAbs specific for CD1d, IL-4, and IL-13 (C) and CD40 and CD154 (D). Results are means 6
SEM from three and six donors for (C) and (D), respectively. *p, 0.05, **p, 0.01, ***p, 0.001 compared with the levels released by B cells cultured in
medium alone except where indicated by bars.
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analysis. We found that coculturing B cells with any of the
iNKT cell subsets in the absence of a-GC did not lead to signif-
icant increases in IFN-g, TNF-a, IL-2, IL-4, IL-5, IL-10, or IL-13
release compared with B cells, iNKT cells, or non-iNKT cells
cultured alone. When a-GC was present, low levels of IFN-g,
TNF-a, IL-4, IL-5, and IL-13, but not IL-2 nor IL-10, were re-
leased by the cocultures of B cells with CD4+ or DN iNKT cells
(Fig. 5A). Although CD4+ iNKT cells induced the expansion of
cells with phenotypes associated with Breg cells (Fig. 4), no IL-10
was detected in the supernatants of these cocultures. When
monocyte-derived DC were used as APCs for a-GC, all subsets of
iNKT cells released the above cytokines, including IL-10, with
100–1000-fold more IFN-g and TNF-a and 10–100-fold more IL-
4, IL-5, and IL-13 released compared with when B cells were used
as APCs (Fig. 5B). It is unlikely that the low amounts of cytokines
produced by cocultures of B cells and iNKT cells are due to
contaminating monocytes or DC, because the B cells were
enriched to purities of .99.5%, as shown by flow cytometric
analysis of CD19 and CD20 expression. These results suggest that
B cells can present a-GC to iNKT cells but are 10–1000 times less
efficient than DC at stimulating cytokine production by the cells.
To determine the cellular sources of these cytokines and further
investigate if the CD1dhiCD5+ B cells that were induced by CD4+
iNKT cells have cytokine profiles typical of Breg cells, total
B cells were cultured for 3 d in medium alone or with equal
numbers of expanded CD4+ iNKT cells in the absence or presence
of a-GC. Monensin was added to the cultures for the final 4 h, and
the expression of IFN-g, IL-10, and IL-4 by gated CD19+ (B) cells
and 6B11+ (iNKT) cells was examined by flow cytometry. Upon
stimulation with B cells pulsed with a-GC, most iNKT cells
produced IFN-g and IL-4, but these cytokines were produced by
,2% of B cells (Fig. 5C). Interestingly, when B cells were
cocultured with CD4+ iNKT cells, up to 1% of the B cells and up
to 2% of the iNKT cells expressed IL-10. However, due to the
small numbers of CD1dhiCD5+ B cells, we were unable to de-
termine with certainty if this putative Breg population was the
source of B cell–derived IL-10. Thus, although B cells present
a-GC to CD4+ iNKT cells, resulting in Th1 and Th2 cytokine
production, CD4+ iNKT cells induce the expansion of B cells with
phenotypes of Breg cells and can induce IL-10 production by
some B cells.
The ability of iNKT cell subsets to produce the TFH cell cytokine
IL-21 was also tested by intracellular staining for IL-21 in
iNKT cell subsets after exposure for 3 d to B cells in the presence
and absence of a-GC. Fig. 5D shows that ,2% of untreated CD4+,
CD8a+, and DN iNKT cells produced IL-21, and these frequencies
were not changed by the addition of B cells or a-GC. Thus, al-
though iNKT cells can provide B cell help for Ab production,
,2% express classical TFH cell phenotypes (Fig 4C) or cytokine
profiles (Fig. 5D).
DN iNKT cells degranulate in the presence of B cells
To determine if subsets of iNKT cells can potentially kill autol-
ogous B cells, total iNKT cells were cultured with equal numbers of
sorted B cells, and cytolytic degranulation by iNKT cell subsets
was measured by CD107a externalization. Fig. 6 shows that CD4+
and CD8+ iNKT cells did not degranulate in response to B cells
whether or not a-GC was present, but these cells expressed
CD107a at the cell surface when stimulated with PMA and ion-
omycin. Surprisingly, DN iNKT cells displayed significant CD107a
FIGURE 4. CD4+ iNKT cells induce the expansion of CD1dhiCD5+ and CD24hiCD38hi B cells. B cells from seven donors were cultured for 3 d in
medium alone or with equal numbers of expanded CD4+, CD8+, or DN iNKT cells in the absence or presence of a-GC. (A) Representative flow cytometry
dot plots showing isotype control mAb staining and FMO for CD1d mAb staining (left panel) and CD1d and CD5 expression (right panel) by gated CD19+
cells. (B) Mean (6 SEM) percentages of B cells that expressed CD1dhiCD5+ (left panel) or CD24hiCD38hi (right panel) phenotypes. *p , 0.05. (C) Mean
(6 SEM) percentages of iNKT cells that expressed CXCR5+PD-1+ TFH phenotypes.
1670 iNKT CELLS INDUCE B CELL DIFFERENTIATION IN VITRO
 at M
aynooth U
niversity (Natl Univ of Ireland) on February 11, 2020
http://w
w
w
.jimmunol.org/
D
ow
nloaded from
 
expression in response to B cells, whether or not a-GC was
present. Thus, it is likely that DN iNKT cells can kill autologous
B cells.
iNKT cells induce expression of activation and costimulatory
markers by B cells
To determine if iNKT cells can induce maturation of B cells into
cells with APC phenotypes, total B cells were cultured for 3 or
10 d in medium alone, with PMA and ionomycin or with equal
numbers of expanded iNKT cells or non-iNKT cells. Changes in
cell-surface expression of CD40, CD83, CD86, CD69, CD80, and
HLA-DR by total B cells and naive, unswitched memory, switched
memory, CD272 memory B cells, and CD1dhiCD5+ and CD24hi
CD38hi B cells were analyzed by flow cytometry. We observed
increased expression of CD40 (p , 0.05), CD95 (p , 0.01),
CD86 (p , 0.05), and CD83 (not significant), but not CD80 nor
HLA-DR on total B cells after 3 d of coincubation with total
iNKT cells (Fig. 7A). After 10 d of coincubation with iNKT cells,
these markers were not expressed at significantly higher levels
than on B cells cultured alone. When non-iNKT cells were
substituted for iNKT cells, the levels of the above-mentioned
markers were similar to those on B cells cultured alone (Fig.
7A). CD40 and CD86 were upregulated on naive, unswitched
memory, switched memory, CD272 memory B cells, and the two
putative Breg cell subsets (CD1dhiCD5+ and CD24hiCD38hi) (data
not shown).
When sorted CD4+, DN, and CD8+ iNKT cells were cultured
with the B cells, only the CD4+ subset was found to significantly
FIGURE 5. Cocultures of a-GC–pulsed B cells and CD4+ or DN iNKT cells produce low levels of IFN-g, TNF-a, IL-4, IL-5, IL-13, and IL-10. (A)
Cytokine levels released by B cells, CD4+, CD8+, and DN iNKT cells and B cells cocultured for 3 d with autologous CD4+, CD8+, and DN iNKT cells in
the absence or presence of a-GC. (B) Cytokine levels released by DC, iNKT cell subsets, and 3-d cocultures of DC and iNKT cells. (C) Flow cytometry dot
plots showing intracellular expression of IFN-g and IL-10 (top panel) and IL-4 (bottom panel) by gated B cells (left panel) and CD4+ iNKT cells (right
panel) cocultured for 3 d in the presence of a-GC. (D) Mean (6 SEM) percentages of CD4+, CD8+, and DN iNKT cells that produced IL-21 after 3 d of
culture with B cells in the absence and presence of a-GC. Bars represent means (6 SEM) from three (A, B) or four (D) independent experiments.
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induce CD40 and CD86 expression, and this occurred only when
a-GC was present. CD8+ and DN iNKT cell subsets also weakly
induced CD86 expression, but whereas CD4+ and DN iNKT cells
required the presence of a-GC to do so, CD8+ iNKT cells did not
(Fig. 7B). Therefore, iNKT cells induce the expression of acti-
vation and costimulatory molecules by B cells, but the CD4+, DN,
and CD8+ iNKT cell subsets differ in their abilities to do so and in
their requirements for ligand activation.
The requirements for cell–cell contact, CD1d, and cytokines in
iNKT cell–mediated upregulation of CD40, CD83, and CD86
expression by B cells were tested using transwell plates and in the
absence or presence of blocking mAbs against CD1d, IL-4, or IL-
13. When B cells and iNKT cells were separated in transwell
plates or when anti-CD1d blocking Abs were added to the iNKT–
B cell cocultures, the upregulation of all three markers was re-
duced (Fig. 7C). Blocking IL-13 resulted in moderate inhibition of
CD86 expression only, but blocking IL-4 had no effect on the
expression of any of these markers.
iNKT cells prevent the induction of T cell proliferation by
B cells
The effect of total iNKT cells on the ability of B cells to promote
proliferation of autologous and allogeneic T cells was investigated
using the CellTrace Violet Cell Proliferation assay (Invitrogen).
B cells that were cultured in medium alone were able to induce
proliferation of autologous T cells in the absence of Ag and to
a greater degree in the presence of PPD, SEB, or PHA (Fig. 8).
However, B cells that were precultured with iNKT cells were
greatly reduced in their ability to induce T cell proliferation.
Nonspecific and PPD-stimulated T cell proliferation was abro-
gated by the presence of iNKT cells, whereas SEB-specific T cell
proliferation was not. Allogeneic T cell proliferation was also
abrogated by iNKT cells. This inhibition of B cell–stimulated
T cell proliferation occurred whether or not a-GC was present in
the iNKT–B cell cocultures.
Discussion
iNKT cells provide cognate and noncognate help for lipid-reactive
and protein-reactive B cells. They are required for the generation of
protective Ab responses against some murine pathogens (14–16),
and they dramatically augment Ab responses to coadministered
Ags in vivo (18–22). These findings have led to interest in
iNKT cells and their ligands as adjuvants for the development of
vaccines and immunotherapies (38, 39). However, despite their
name, iNKT cells are heterogeneous and multifunctional in na-
ture. Human CD4+, CD8a+, and DN iNKT cells can release Th1
(IFN-g and TNF-a) and Th2 (IL-4, IL-5, and IL-13) cytokines
when activated with a-GC presented by CD1d+ cells. The relative
amounts of the cytokines follow a striking CD8a . DN . CD4
pattern for Th1 and a CD4 . DN . CD8a pattern for Th2,
whereas CD4+ iNKT cells, only, produce IL-9 and IL-10 (11, 13,
27). These variable Th cell cytokine profiles prompted us to
compare the relative abilities of CD4+, CD8a+, and DN iNKT cell
lines to provide help for B cell differentiation and Ab production
in vitro. We also have investigated the influence iNKT cell subsets
FIGURE 6. DN iNKT cells can kill autologous B cells. Mean (6 SEM)
percentages of CD4+ (top panel), CD8a+ (middle panel), and DN (bottom
panel) iNKT cells from four donors that express cell-surface CD107a after
culture in medium alone or with autologous B cells in the absence and
presence of PMA and ionomycin (PMA/I) and a-GC.
FIGURE 7. NKT cells induce upregulation of activation and costimu-
latory molecules by B cells. B cells were cultured in medium alone, with
PMA and ionomycin, or with equal numbers of expanded iNKT cells or
non-iNKT cells for 3–10 d. Changes in cell-surface expression of CD40,
CD83, CD86, CD69, and CD80 by gated B cells (CD19+) were analyzed
by flow cytometry. (A) Offset histogram overlays showing mean fluores-
cence intensity (MFI) of staining of gated B cells with mAbs specific for
the indicated markers or isotype control mAb (top histograms) after cul-
turing B cells (from second from top to bottom histograms) in medium
alone or with PMA and ionomycin, iNKT cells, or non-iNKT cells. (B) Bar
graphs showing average (6 SEM) MFI of staining for CD40 and CD86
expression by B cells from seven donors after incubation for 3 d with
medium alone or with autologous CD4+, CD8+, or DN iNKT cells, in the
absence or presence of 100 ng/ml a-GC. (C) MFI of CD40 (left panel) and
CD86 (right panel) expression by B cells from six donors cultured for 3
d in medium alone or with iNKT cell in the absence or presence of
blocking mAbs specific for CD1d, IL-4, and IL-13. *p , 0.05 compared
with MFI on B cells cultured in medium alone, **p , 0.01.
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have on cytokine production, Ag presentation, and T cell activa-
tion by B cells.
Two previous in vitro coculture studies of B cells with fresh (29)
and expanded (28) human iNKT cells and one on murine
iNKT cells (40) have shown that iNKT cells can induce Ab pro-
duction by human B cells in vitro. We found that all subsets of
expanded iNKT cell lines induced the secretion of IgG (both IgG1
and IgG2), IgA, and IgM by autologous B cells. Also observed by
Galli and coworkers (28), we found that IgE was not induced by
any of the three iNKT cell subsets. This may reflect a need for
conventional CD4+ T cells, which are required for iNKT cell–
mediated IgE production by murine B cells (41). iNKT cell–me-
diated help for B cells required cell–cell contact and CD1d, but
did not appear to involve CD40–CD154 interaction, and it was not
inhibited by neutralizing Abs against IL-4 or IL-13. These find-
ings compare and contrast with those from in vivo studies in mice
immunized with a-GC and protein Ag, which showed that
iNKT cell–mediated B cell help required B cell expression of
CD1d (21, 24, 42) and CD40 (24, 37) but did not require IL-4
(24). iNKT cell–mediated enhancement of Ab responses in vivo
also required DC but did not require the expression of CD1d by
DC (43). Another difference between these in vivo models of
a-GC–mediated B cell help and our system is that a-GC was not
required for iNKT cell–mediated B cell help in vitro. Galli and
coworkers (28) also found that human CD4+ iNKT cells, in the
absence or presence of Ag, induced IgM production by B cells
in vitro. Our findings confirm that the direct interaction between
iNKT cells and B cells is sufficient to stimulate Ab production in
vitro and that exogenous Ag is not required.
The ability of iNKT cells to provide B cell help for Ab pro-
duction prompted us to examine whether these iNKT cells express
CXCR5+PD-1+ phenotypes of TFH cells or produce IL-21,
attributes that are associated with murine iNKT cells stimulated
in vivo with a-GC (25, 36, 37). We found that up to 2% of ex-
panded iNKT cells expressed TFH phenotypes or released IL-21,
and this frequency was not increased by coculturing them with
B cells in the absence or presence of a-GC. Similar proportions of
iNKT cells displaying TFH phenotypes were found in mice im-
munized with Ag and a-GC (36, 37).
The ability of iNKT cells to induce Ab secretion by B cells
highlights them as potential targets for therapeutic boosting of
Ab responses in vaccines and infections or inhibition of pathogenic
Ab production in autoimmune and allergic disease. Devera and
coworkers (42) exploited iNKT help to B cells to enhance and
sustain neutralizing Ab responses toward the Bacillus anthracis
lethal toxin, which led to sustained survival and good health in
mice challenged with the toxin. However, because of the multiple
effector and immunoregulatory activities of iNKT cells, a com-
plete understanding of the mechanisms underlying the interaction
between iNKT cells and B cells is essential to predict or program
the outcomes in vivo.
Activation of human iNKT cells requires the presence of im-
mature but not mature B cells (44). However, we found that CD1d
is expressed at comparable levels by mature, plasma, memory, and
B-1 B cells, suggesting that all B cell subsets can present glyco-
lipids to iNKT cells. CD4+ iNKT cells were found to promote
expansions of unswitched (IgD+) memory B cells in a contact-
dependent manner, resulting in decreased frequencies of naive
B cells. Despite inducing Ab release by B cells, none of the
iNKT cell subsets induced significant expansions of switched
(IgD2) memory B cells or the expression of IgM or IgG by any
memory B cell subset. This suggests that iNKT cells promote Ab
release by class-switched memory B cells rather than inducing
class switching. Thus, it appears that iNKT cells may interact
differently with naive and memory B cells, promoting differenti-
ation of naive B cells into unswitched memory cells that are not
required for iNKT cell activation while promoting differentiation
of switched memory B cells into Ab-secreting plasma cells. Future
experiments involving stimulation of B cells with iNKT cell
subsets followed by detection of specific Ab-secreting memory
B cells are required to confirm that iNKT cells can restimulate
memory B cells.
We investigated if iNKT cells could induce the expansion of
putative Breg cells. The CD1dhiCD5+ B cell phenotype defines
a subset of murine B cells that downregulate immune responses
via secretion of IL-10 and inhibit the development of autoimmune
disease (34, 45, 46). In humans, an IL-10–producing B cell pop-
ulation that inhibits Th1 cell differentiation resides in the CD24hi
CD38hi B cell compartment, and this subset is impaired in patients
with systemic lupus erythematosus (35, 47). The majority of hu-
man CD1dhiCD5+ B cells are reported to be contained in the
CD24hiCD38hi B cell subset (35); therefore, we investigated both
subsets as putative Breg cells. We found that coculturing B cells
with total iNKT cells did not significantly affect CD1d expression.
However, CD4+ iNKT cells induced the expansion of a population
of CD1dhiCD5+ B cells by a mechanism that required cell–cell
contact but not activation of the iNKT cells with a-GC. CD4+
iNKT cells in the presence of a-GC also induced a moderate
expansion of CD24hiCD38hi B cells. Although, we did not detect
IL-10 in the supernatants of cocultures of CD4+ iNKT cells with
FIGURE 8. iNKT cells inhibit the induction of T cell proliferation by B
cells. B cells were cocultured with equal numbers of autologous
iNKT cells in the absence or presence of 100 ng/ml of a-GC for 3 d. B
cells and iNKT cells were also cultured separately in medium alone as
negative controls. The cocultured cells were harvested, washed, and used
as stimulators of sorted autologous or allogeneic conventional CD3+
T cells that were labeled using the CellTrace Violet (Invitrogen). The
T cells were cultured with the B/iNKT cells at a ratio of 3:1 with medium
only, 10 mg/ml PPD, 1 mg/ml SEB, or 5 mg/ml PHA. Proliferation of the
T cells was assayed by flow cytometric examination of dilution of the
CellTrace dye after 6 d in culture. Plots are representative of three inde-
pendent experiments.
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B cells using multiplex CBA analysis, up to 1% of the B cells in
these cultures expressed intracellular IL-10. IL-10 production is
a hallmark feature of Breg cells (34, 35, 48–50). We were unable
to show convincingly that this IL-10 was produced by the CD1dhi
CD5+ subset of B cells; however, our data indicate that CD4+
iNKT cells induced IL-10 production by some B cells, suggesting
that they promote Breg cell differentiation. We also found that up
to 1 ng/ml of IL-10 was released by cocultures of DC with all
subsets of iNKT cells, suggesting that iNKT cells can induce reg-
ulatory DC as well as B cells.
DC can present a-GC to iNKT cells resulting in the rapid se-
cretion of Th1 and Th2 cytokines in vivo and in vitro (7, 8, 13, 32)
(Fig. 5B). However, experiments aimed at demonstrating that
B cells can similarly present a-GC and induce cytokine produc-
tion by iNKT cells have been conflicting. Bialecki and coworkers
(51) reported no IFN-g or IL-4 production by cocultures of murine
iNKT cells and marginal zone B (MZB) cells presenting a-GC
in vitro, but both cytokines were produced when DC were added.
Two other studies demonstrated weak Th2 (IL-4 and IL-13) pro-
duction by murine iNKT cells after stimulation with a-GC–pulsed
total B cells (52) or MZB cells (53) in vitro and in vivo, and these
cytokine profiles were skewed toward Th1 when DC were present.
We found that when a-GC–pulsed human B cells were cultured
with CD4+ or DN iNKT cells, but not CD8+ iNKT cells, IFN-g,
TNF-a, IL-4, IL-5, and IL-13 were secreted into the supernatants.
Using intracellular cytokine staining and flow cytometry, we
showed that iNKT cells are the main source of these cytokines.
However, the amounts of cytokines released were 10–1000-fold
lower than those when DC were used as APC for a-GC. Glyco-
lipid presentation by B cells appears to be required for optimal
activation of iNKT cells by DC, because removal of MZB cells
reduced iNKT cell activation by murine spleen cells pulsed with
a-GC in vitro (51), and human PBMC depleted of B cells failed to
support iNKT cell expansion and cytokine release in response to
a-GC (44). In contrast, Bezbradica and coworkers (52) reported
that B cells suppressed murine DC-mediated iNKT cell activation
in vivo. Collectively, these findings support the view that B cells
can present glycolipid Ags to iNKT cells, but rather than being
potent stimulators of cytokine secretion, B cells modulate cyto-
kine production by iNKT cells activated by DC. Reciprocally,
iNKT cells can induce cytokine production by DC (7, 8, 32) and
by small proportions of B cells.
Because CD8+ and DN iNKT cells and, to a lesser degree, CD4+
iNKT cells are potent cytotoxic T cells capable of killing CD1d+
cells presenting a-GC (13), we investigated if these iNKT cell
subsets could kill autologous B cells presenting this glycolipid.
Interestingly, only the DN subset of iNKT cells degranulated in
response to B cells, and this occurred whether a-GC was present
or not. Thus, although iNKT cells can promote Ab production by
B cells, DN iNKT cells may regulate this activity by killing the
B cells.
iNKT cells can induce maturation of DC into APC that express
costimulatory and adhesion molecules and can prime naive con-
ventional T cells (7, 8, 32). B cells are also professional APCs
(30), and they express CD1d; therefore, we investigated the in-
fluence that iNKT cells and their subsets have on the APC func-
tion of B cells. Extending the findings of Kitamura and coworkers
(54), we found that iNKT cells induced the expression of CD40,
CD69, CD83, and CD86, but not CD80 nor HLA-DR, on B cells
by a mechanism that was dependent on cell–cell contact and
CD1d. Of the three iNKT cell subsets, CD4+ iNKT cells were the
most potent inducers of costimulatory molecule expression by
B cells. Blocking IL-13 resulted in moderate inhibition of CD86
expression, but blocking IL-4 had no effect on the expression of
these markers by B cells. These phenotypic changes suggest that
iNKT cells induce maturation of B cells into APCs. We found that
B cells presented Ags, superantigens, and mitogens to T cells
resulting in their proliferation. However, B cells that were pre-
cultured with iNKT cells were greatly reduced in their ability to
induce T cell proliferation. Nonspecific and PPD-stimulated T cell
proliferation was abrogated by iNKT cells, whereas SEB-specific
T cell proliferation was not. As SEB does not require intracellular
processing to be presented on MHC, our results suggest that
iNKT cells may inhibit intracellular Ag processing by B cells.
Allogeneic T cell proliferation was also abrogated by iNKT cells.
This inhibition of B cell–stimulated T cell proliferation occurred
whether or not a-GC was present in the iNKT–B cell cocultures.
These data are consistent with a model in which iNKT induce the
differentiation of B cells into tolerogenic APC that inhibit con-
ventional T cell activation. Subsets of B cells that are tolerogenic
APCs have been described (55, 56), and although not shown in
this study, it is possible that the induction of T cell proliferation by
B cells may be inhibited by CD1dhiCD5+ Breg cells or by IL-10
released by other B cells.
CD4+ T cell help for B cells is a key requirement for the
generation of Ab-secreting plasma cells and memory B cells. The
interaction between the two cells generally takes place in sec-
ondary lymphoid organs, involves presentation of processed Ag by
the B cell to the T cell, signaling through costimulatory molecules
such as CD40, and the production of cytokines (1–3). Our study
demonstrates that human B cells can present glycolipid Ag to
iNKT cells, resulting in low-level Th1 and Th2 cytokine secretion
in vitro. Reciprocally, iNKT cells can have diverse effects on
B cells, depending on the iNKT cell subset, on whether glycolipid
Ag is added and possibly on the differentiation status of the B cell.
Firstly, CD4+, CD8+, and DN iNKT cells can all stimulate Ab
production by B cells by a mechanism that requires CD1d but not
exogenous glycolipid Ag nor CD40–CD154 interaction. Secondly,
CD4+ iNKT cells in the presence of glycolipid Ag promote dif-
ferentiation of naive B cells into memory cells, but they do not
appear to promote Ig isotype switching by these cells. Thirdly,
CD4+ iNKT cells in the absence of exogenous glycolipid Ag in-
duce the expansions of B cells that exhibit phenotypes of Breg
cells and B cells that produce IL-10, whereas DN iNKT cells in
the absence of added glycolipid may kill autologous B cells. Fi-
nally, iNKT cells (and in particular the CD4+ subset) induce
maturation of all B cell subsets into cells with APC phenotypes,
but these APCs fail to stimulate proliferation of conventional
T cells, as seen when untreated B cells are used. Collectively,
these results indicate that the presence of exogenous a-GC is
a major determinant of the outcome of B–iNKT cell interactions:
in the presence of a-GC, B cells promote cytokine secretion by
iNKT cells, which will boost T cell–mediated immunity, whereas
in the absence of a-GC, iNKT cell activation by B cells results in
Ab-mediated immune responses and suppression of T cell–medi-
ated immunity. The dependence of these functional outcomes on
the absence or presence of a-GC raises the question of how other
glycolipid Ags will modify B cell responses to iNKT cells, and in
this regard, several chemical analogs of a-GC that can skew cy-
tokine responses of iNKT cells are being tested as potential
immunomodulators for the treatment of disease (32, 57, 58). The
diverse outcomes of iNKT–B cell interactions have important
implications for therapy for autoimmune disease, in which in-
duction of Breg cells or prevention of pathogenic Ab responses
may be beneficial (34, 35, 45, 46, 48–50), and for cancer and
infectious disease, in which T cell responses are required (4, 5).
The presence of iNKT cell subsets with opposing roles in immune
responses might explain why clinical trials involving these cells to
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date have been unsuccessful (38, 39). Therapeutic manipulation of
iNKT cells may necessarily require the sorting of iNKT cells into
functionally-distinct subsets and/or selective activation of partic-
ular effector functions using customized glycolipid Ags.
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